Abstract Vosoritide is the first precision medical therapy approved to increase growth velocity in children with achondroplasia. Sharing early prescribing experiences across different regions could provide a framework for developing practical guidance for the real-world use of vosoritide. Two meetings were held to gather insight and early experience from experts in Europe, the Middle East, and the USA.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Vienna Bone
Evaluation of bone mineral density and bone turnover in children on anticoagulation
Katharina Thom1 Janina Maria Patsch2 Florentina Haufler3,4 Christiane Pees1 Sulaima Albinni1 Michael Weber2 Christoph Male1 Adalbert Raimann3,4* 1Division of Pediatric Cardiology and Haemostaseology, Department of Pediatric and Adolescent Medicine, Medical University of Vienna, Vienna, Austria 2Division of General and Pediatric Radiology, Department of Biomedical Imaging and Image Guided Therapy, Medical University of Vienna, Vienna, Austria 3Vienna Bone and Growth Center, Vienna, Austria...
Investigating the role of ASCC1 in the causation of bone fragility
1 Introduction The activating signal co-integrator 1 complex subunit 1 (ASCC1; MIM: 614215) gene encodes one subunit of the tetrameric activating signal co-integrator 1 (ASC-1) ribonucleoprotein complex including also ASCC2 (MIM: 614216), ASCC3 (MIM: 614217), and TRIP4 (MIM: 604501) (1). In general, signal co-integrators can act bidirectionally as either transcriptional coactivator or corepressor.
Evaluation of Bone Mineral Density and Bone turnover in children on anticoagulation
Evaluation of Bone Mineral Density and Bone turnover in children on anticoagulation 1Medical University of Vienna, Austria 2Vienna Bone and Growth Center, Austria The final, formatted version of the article will be published soon. Notify me Receive an email when it is updated You just subscribed to receive the final version of the article Background: Childhood and adolescence are critical periods of bone mineral acquisition.
Investigating the role of ASCC1 in the causation of bone fragility
Investigating the role of ASCC1 in the causation of bone fragility Barbara Voraberger1 , Johannes A. Mayr2 , Nadja Fratzl-Zelman3, 4 , Stéphane Blouin5 , Suma Uday6 , Robert Kopajtich7, 8 , Marijke Koedam9 , Helena Hödlmayr1 , Saskia B.
The ankle in XLH: reduced motion, power and quality of life
Celine C. Akta1, 2, 3, Florian Wenzel-Schwarz1, 2, Alexandra Stauffer1, 2, Andreas Kranzl2, 4, Adalbert Raimann2, 5, Roland Kocijan2, 3, 6, Rudolf Ganger1, 2 and Gabriel T.
A neomorphic variant in SP7 alters sequence specificity and causes a high-turnover bone disorder - Nature Communications
Abstract SP7/Osterix is a transcription factor critical for osteoblast maturation and bone formation. Homozygous loss-of-function mutations in SP7 cause osteogenesis imperfecta type XII, but neomorphic (gain-of-new-function) mutations of SP7 have not been reported in humans. Here we describe a de novo dominant neomorphic missense variant (c.926 C > G:p.S309W) in SP7 in a patient with craniosynostosis, cranial hyperostosis, and long bone fragility.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Vienna
Contact Vienna, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack